Unknown

Dataset Information

0

Ridaforolimus.

ABSTRACT: Ridaforolimus (AP23573; MK 8669) is an analog of sirolimus and a small molecule inhibitor of the mammalian target of rapamycin for the treatment of cancer. Both intravenous and oral formulations of the compound are being tested in clinical trials for the treatment of soft-tissue and bone sarcomas. It is in phase III development for sarcoma in the EU and US, and phase II for breast cancer, endometrial cancer, non-small cell lung cancer, and prostate cancer in the US and other markets in the world. This review discusses the key development milestones and therapeutic trials of this drug.

SUBMITTER:  

PROVIDER: S-EPMC3586089 | biostudies-literature | 2010

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Ridaforolimus.

Drugs in R&D 20100101 3

Ridaforolimus (AP23573; MK 8669) is an analog of sirolimus and a small molecule inhibitor of the mammalian target of rapamycin for the treatment of cancer. Both intravenous and oral formulations of the compound are being tested in clinical trials for the treatment of soft-tissue and bone sarcomas. It is in phase III development for sarcoma in the EU and US, and phase II for breast cancer, endometrial cancer, non-small cell lung cancer, and prostate cancer in the US and other markets in the world  ...[more]

Similar Datasets

Unknown A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
| S-EPMC5709225 | biostudies-literature
Unknown Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis).
| S-EPMC5975379 | biostudies-literature
Unknown Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.
| S-EPMC10926822 | biostudies-literature
Unknown A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.
| S-EPMC5356695 | biostudies-literature
Unknown Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.
| S-EPMC3313018 | biostudies-literature
Transcriptomics Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
2016-07-01 | GSE79492 | GEO
Unknown Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.
| S-EPMC3619076 | biostudies-literature
Unknown A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.
| S-EPMC3456920 | biostudies-literature
Unknown Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 5-Year Outcomes From the BIONICS and NIREUS Trials.
| S-EPMC11681401 | biostudies-literature
Unknown Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
| S-EPMC5465458 | biostudies-literature